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Tau is a major microtubule-associated protein of axons and is also the principal component of the paired helical filaments (PHFs) that
comprise the neurofibrillary tangles found in Alzheimer’s disease and other tauopathies. Besides phosphorylation of tau on serine and
threonine residues in both normal tau and tau from neurofibrillary tangles, Tyr-18 was reported to be a site of phosphorylation by the
Src-family kinase Fyn. We examined whether tyrosine residues other than Tyr-18 are phosphorylated in tau and whether other tyrosine
kinasesmight phosphorylate tau. Usingmass spectrometry, we positively identified phosphorylated Tyr-394 in PHF-tau from anAlzhei-
mer brain and in human fetal brain tau. When wild-type human tau was transfected into fibroblasts or neuroblastoma cells, treatment
with pervanadate caused tau to become phosphorylated on tyrosine by endogenous kinases. By replacing each of the five tyrosines in tau
with phenylalanine, we identified Tyr-394 as the major site of tyrosine phosphorylation in tau. Tyrosine phosphorylation of tau was
inhibited by PP2 (4-amino-5-(4-chlorophenyl-7-(t-butyl)pyrazolo[3,4-d]pyrimidine), which is known to inhibit Src-family kinases and
c-Abl. Cotransfectionof tau andkinases showed thatTyr-18was themajor site for Fynphosphorylation, butTyr-394was themain residue
for Abl. In vitro, Abl phosphorylated tau directly. Abl could be coprecipitated with tau and was present in pretangle neurons in brain
sections fromAlzheimer cases. These results show that phosphorylation of tau on Tyr-394 is a physiological event that is potentially part
of a signal relay and suggest that Abl could have a pathogenic role in Alzheimer’s disease.
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Introduction
Tau protein is predominantly expressed in axons, where it binds
to and stabilizes microtubules (Bue´e et al., 2000), and is also the
main component of paired helical filaments (PHFs). PHFs form
neurofibrillary tangles (NFTs) that are a pathological feature of
Alzheimer’s disease (AD) (Smith andAnderton, 1994; Bue´e et al.,
2000) and several other “tauopathies” (Spillantini and Goedert,
1998; Delacourte and Bue´e, 2000). These include frontotemporal
dementia with parkinsonism linked to chromosome 17, the pa-
tients ofwhich havemutations in the tau gene itself (Hutton et al.,
1998; Poorkaj et al., 1998), suggesting that tau has an important
role in these neurodegenerative diseases, including AD.
Phosphorylation on at least 25 serine and threonine residues
has been reported in tau isolated from an Alzheimer brain
(Morishima-Kawashima et al., 1995; Hanger et al., 1998; Ander-
ton et al., 2001). Tau hyperphosphorylation hinders its ability to
bind to microtubules (Biernat et al., 1993). Tau in PHF (PHF-
tau) is abnormally hyperphosphorylated, and it is hypothesized
that this hyperphosphorylation contributes to neurodegenera-
tion through the destabilization of microtubules. Several candi-
date kinases have been identified that can phosphorylate tau on
sites found to be phosphorylated in PHF-tau (Lovestone and
Reynolds, 1997). These include cyclin-dependent kinase 5 (cdk5)
(Maccioni et al., 2001) and glycogen synthase kinase-3 (Anderton
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et al., 2001). Recent studies with transgenic animals further sup-
port a key role for cdk5 (Noble et al., 2003) and glycogen synthase
kinase-3 (Spittaels et al., 2000; Lucas et al., 2001) in the formation
of NFTs.
There is now evidence that phosphorylation of tau on tyrosine
residues may also occur. Human tau has five tyrosines (18, 29,
197, 310, and 394; numbered according to the sequence of the
longest CNS isoform), andphosphorylation by the kinase Fynhas
been demonstrated in cell models (Lee et al., 1998). We have
shown previously that PHF-tau from some AD cases contains
tyrosine-phosphorylated tau, and that treatment of cultured neu-
rons with amyloid- peptide (A) induced tyrosine phosphory-
lation of several proteins, including tau (Williamson et al., 2002).
Using cotransfection to express Fyn along with deletion frag-
ments of tau, a recent study showed that Tyr-18 was one of the
tyrosine residues phosphorylated by Fyn in COS-7 cells (Lee et
al., 2004). Moreover, immunocytochemical studies indicated
that tau phosphorylated onTyr-18was present inNFTs in theAD
brain (Lee et al., 2004). Using mass spectrometry, however, we
identified phosphorylated Tyr-394 in both PHF-tau and in tau
from a fetal brain. We used the tyrosine phosphatase inhibitor
pervanadate in tau-transfected cells and found that Tyr-394 is the
main tyrosine phosphorylated on tau in these cells. In cotrans-
fected cells, Fyn phosphorylated predominantly Tyr-18, but
c-Abl phosphorylated tau predominantly on Tyr-394. Recently,
A has been shown to activate Abl in hippocampal neurons (Al-
varez et al., 2004), and we report elevated Abl in pretangle neu-
rons in AD. Therefore, our findings suggest that Ablmediates the
A-induced increase in tau tyrosine phosphorylation (William-
son et al., 2002) and opens new insights into the physiological
function of tau and into its role in neurodegenerative disorders.
Materials andMethods
Preparation of human tau. The frozen cortex from an AD brain was
supplied by the Medical Research Council Neurodegenerative Diseases
Brain Bank, and PHF-tau was purified by Mono Q chromatography and
reversed-phase HPLC as described previously (Hanger et al., 1998).
Brain tissue from an 18-week-old fetus was removed and placed in
Hanks’ buffered saline solution for1 h at 4°C and then frozen in liquid
nitrogen and stored at 70°C. Tissue was thawed and homogenized in
ice-cold 2-(N-morpholino) ethanesulfonic acid (Mes; 100 mM), pH 6.5,
containing 0.5 mM MgCl2, 1 mM EGTA, 1 M NaCl, 50 mM N-acetyl glu-
cosamine, 20 mM NaF, 10 mM Na pyrophosphate, 50 mM imidazole, 25
mM -glycerol phosphate, 2 mM dithiothreitol, 5 M okadaic acid, and 1
mM phenylmethanesulfonyl fluoride using1 ml of buffer/g tissue. The
homogenate was centrifuged at 100,000 g(av) for 1 h at 4°C. The super-
natant was heated at 100°C for 10 min, cooled for 10 min in ice, and
centrifuged at 100,000 g(av) for 30 min at 4°C. Heat-stable proteins in
the supernatant were precipitated using 45% saturated ammonium sul-
fate. The pellet was redissolved in 100 mM Mes buffer as above but with-
out NaCl, and perchloric acid was added to a final concentration of 2.5%
(w/w). The supernatant containing acid-soluble proteins was dialyzed
into 50 mM ammonium bicarbonate, centrifuged to remove insoluble
material, and stored at70°C.
Tau cDNA constructs. A construct of human tau 2N4R (longest brain
isoform) was donated by M. Goedert (Medical Research Council Labo-
ratory of Molecular Biology, Cambridge, UK). Recombinant tau 2N4R
was expressed in Escherichia coli BL21 (DE3) and purified as described
previously (Mulot et al., 1994).
For expression inmammalian cells, the cDNAcoding forwild-type tau
2N4Rwas subcloned into the pcDNA3.1/V5-His-TOPO vector (Invitro-
gen, Paisley, UK), yielding a construct with C-terminal V5 and His tags.
To generate the five tau constructs, eachwith a single tyrosine replaced by
phenylalanine, a QuikChange XL site-directed mutagenesis kit (Strat-
agene, Amsterdam, The Netherlands) was used. Primers were as follows:
to convert Tyr-18 to Phe (giving tau construct Y18F), forward primer
5-CAC GCT GGG ACG TTC GGG TTG GGG GAC-3 (Primer A) and
reverse primer 5-GTCCCCCAACCCGAACGTCCCAGCGTG-3; to
convert Tyr-29 to Phe (giving Y29F), forward primer 5-GATCAGGGG
GGCTTCACCATGCACCAAG-3 (Primer B) and reverse primer 5-C
TTG GTG CAT GGT GAA GCC CCC CTG ATC-3; to convert Tyr-197
to Phe (giving Y197F), 5-GAT CGC AGC GGC TTC AGC AGC CCC
GG-3 (Primer C) and reverse primer 5-CC GGGGCT GCTGAAGCC
GCT GCG ATC-3; to convert Tyr-310 to Phe (giving Y310F), forward
primer 5-GGC AGT GTG CAA ATA GTC TTC AAA CCA GTT GAC
CTG AG-3 (Primer D) and reverse primer 5-CT CAG GTC AAC TGG
TTTGAAGAC TAT TTGCACACTGCC-3; and to convert Tyr-394 to
Phe (giving Y394F), forward primer 5-GCG GAG ATC GTG TTC AAG
TCG CCA GTG G-3 (Primer E) and reverse primer 5-C CAC TGG
CGA CTT GAA CAC GAT CTC CGC-3. The sequence of the full insert
was determined for each construct.
To change all five tyrosines to phenylalanines, a QuikChange
multisite-directed mutagenesis kit (Stratagene) was used, with the five
primers A to E (see above). Plasmids were sequenced, and in addition to
identifying constructs in which all five tyrosines had been replaced by
phenylalanine (TauYallF), constructs with a single tyrosine remaining
were produced that contained four phenylalanines and only Tyr-18, Tyr-
29, or Tyr-197. Mutants containing only Tyr-310 or only Tyr-394 were
generated from the TauYallF construct by single site-directed mutagen-
esis as above using the following primers: for Tyr-310only, forward
primer 5-GGC AGT GTG CAA ATA GTC TAC AAA CCA GTT GAC
CTG AG-3 and reverse primer 5-CT CAG GTC AAC TGG TTT GTA
GACTATTTGCACACTGCC-3; and for Tyr-394only, forward primer
5-GCG GAG ATC GTG TAC AAG TCG CCA GTG G-3 and reverse
primer 5-CCACTGGCGACTTGTACACGATCTCCGC-3. The five
constructs with one remaining tyrosine were termed Y18only, Y29only,
etc, and their tau-coding sequences were verified by sequencing.
Other cDNA constructs. Fyn cDNA was a gift from D. Markby (Sugen,
San Francisco, CA), Src cDNAwas obtained fromUpstate Ltd (Src cDNA
allelic pack; Upstate Ltd, Milton Keynes, UK), and c-Abl and c-AblXB
cDNA [a constitutively active form of c-Abl, with deletion of most of the
Src homology 3 (SH3) domain] have been described previously (Jackson
and Baltimore, 1989; Daley et al., 1992).
Antibodies and other materials. Monoclonal anti-V5 antibody was
from Invitrogen (Paisley, UK). Monoclonal antibodies to phosphoty-
rosine (4G10 and P-Tyr-100) were obtained from Upstate Ltd and from
Cell Signaling Technology (Hitchin, UK), respectively. The TP70 poly-
clonal antibody to tau has been described previously (Brion et al., 1993).
The following commercially available phosphospecific antibodies were
used: polyclonal antibody to the autophosphorylated form of Src-family
kinases (Phospho-Src family, Tyr 416; Cell Signaling Technology), poly-
clonal antibody to the phosphorylated form of c-Abl (pY412; Biosource,
Nivelles, Belgium), and AT8 monoclonal to phosphorylated tau
(pSer202/pThr205; Innogenetics, Gent, Belgium). Polyclonal antibody
to Src-family kinases (SRC-2) and monoclonal (s.c.-23) and polyclonal
(K-12) antibodies to c-Abl were obtained from Santa Cruz Bio-
technology (Santa Cruz, CA). 4-Amino-5-(4-chlorophenyl-7-
(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2), 4-amino-7-phenylpyrazol
[3,4-d]pyrimidine (PP3), sodium orthovanadate, and Tween 20 were
obtained from Calbiochem (La Jolla, CA) (Merck Biosciences, Notting-
ham, UK), protein-G Sepharose 4 fast flow was obtained from Amer-
sham Biosciences (Chalfont St. Giles, UK), and Nonidet P-40 (NP-40),
hydrogen peroxide, and catalase were obtained from Sigma-Aldrich
(Poole, UK).
Vanadate stock solution was prepared as a 200mM solution of sodium
orthovanadate and was adjusted to pH 10.0 and heated until the solution
turned colorless. The pH was then readjusted to 10.0, and the previous
steps were repeated until the solution remained colorless and the pHwas
stabilized at 10.0. Sodium orthovanadate was then stored as aliquots at
20°C (Gordon, 1991). Pervanadate was prepared as a 100 stock by
adding 50 l of 200 mM sodium orthovanadate and 1.6 l of 30% (w/w)
hydrogen peroxide to 948 l of water for 5 min at room temperature,
giving 10 mM sodium orthovanadate and 16.3 mM hydrogen peroxide.
After 5 min at room temperature, the excess hydrogen peroxide was
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removed by adding 200 g/ml catalase (520 U/ml) and incubating for
an additional 5 min (Huyer et al., 1997).
Mass spectrometry. Tau from PHF and human fetal tau were resolved
by one-dimensional SDS-PAGE and stained with Brilliant Blue G colloi-
dal concentrate (Sigma). The bands corresponding to tau were excised,
reduced, alkylated, and digestedwith either trypsin or Asp-N (Betts et al.,
1997; Shevchenko et al., 2002). Tau peptides were extracted from the gel
pieces with two wash cycles of 50 mM ammonium bicarbonate and ace-
tonitrile. The extract was pooledwith the initial supernatant, lyophilized,
and resuspended in 20–25 l of 50 mM ammonium bicarbonate.
Peptide digests were analyzed by on-line liquid chromatography tan-
dem mass spectrometry (LC/MS/MS). Chromatographic separations
were performed using an Ultimate LC system (Dionex, Camberley, UK).
Peptides were resolved by reversed-phase chromatography on a 75 m
(inner diameter) C18 PepMap column. A gradient of acetonitrile in
0.05% formic acid was delivered over 60 min to elute the peptides at a
flow rate of 200 nl/min. Peptides were ionized by electrospray ionization
using a Z-spray source fitted to a QTof-micro (Waters Ltd, Elstree, UK).
The instrument was set to run in automated switching mode, selecting
precursor ions based on their intensity and charge state, for sequencing
by collision-induced fragmentation. The MS/MS analyses were con-
ducted using collision energy profiles that were chosen based on the
mass/charge (m/z) and the charge state of the peptide and optimized for
phosphorylated peptides.
The mass spectral data were processed into peak lists containing the
m/z value of each precursor ion, its charge state, and the corresponding
fragment ionm/z values and intensities. The data were searched against a
custom-built database containing the different isoforms of tau using the
Mascot searching algorithm (Matrix Science, Oxford, UK). Peptides and
phosphopeptides of tau were identified based on the search criteria set
(i.e., the cleavage enzyme used with up to three missed cleavages, carb-
amidomethyl modification of cysteine residues, and oxidized methio-
nine). Phosphorylated peptides were identified by selecting for tyrosine
and serine/threonine phosphorylation as a variable modification. The
exact location of phosphorylation within each peptide was determined
by the pattern of fragment ions produced (b series and y series, from the
N and C termini, respectively) (Roepstorff and Fohlman, 1984); this
typically involved visual verification of individual MS/MS spectra.
For PHF-tau, additional supporting evidence was obtained for the
phosphorylation of Tyr-394 using the 4000QTRAP mass spectrometer
(Applied Biosystems, Darmstadt, Germany), interfaced to an Ultimate
LC system with the chromatography performed as described above.
Chromatographic separation of two distinct forms of the doubly phos-
phorylated peptide TDHGAEIVpYKSPVVSGDTpSPR and TDH-
GAEIVYKpSPVVSGDTpSPR was achieved, and separate enhanced
product ion (EPI) spectra were recorded for each phosphopeptide. The
MS/MS fragment ions clearly defined the sites of phosphorylation in each
case.
Cell culture, transfection, and immunoprecipitation. COS-7 cells were
cultured in DMEM supplemented with 10% (v/v) fetal calf serum, 2 mM
L-glutamine, 10 U/ml penicillin, and 10g/ml streptomycin. cDNA vec-
tors were introduced into COS-7 cells by lipofectamine transfection.
Cells were transfected at 90%confluencywith 8.6g ofDNAand 15l of
lipofectamine per 60 mm dish in Optimem (Invitrogen) for 5 h. Human
neuroblastoma SHSY5Y cells were cultured in DMEM F-12 medium
with 15% (v/v) fetal calf serum, with glutamine and antibiotics as for
COS-7 cells. Cells were transfected at 60–70% confluency as for COS-7
cells, except that lipofectamine was replaced with 10l of lipofectamine-
2000. For cotransfection experiments, Chinese hamster ovary (CHO)
cells were cultured in F-12 nutrient mixture with 10% (v/v) fetal calf
serum, 10 U/ml penicillin, and 10 g/ml streptomycin. Cells were trans-
fected at 70% confluency with the same protocol used for COS-7 cells.
Transiently transfected cells were harvested in NETF buffer (100 mM
NaCl, 2 mM EGTA, 50 mM Tris-Cl, pH 7.4, and 50 mM NaF) containing
1% (v/v) NP-40, 2 mM orthovanadate, and protease inhibitors (Com-
plete; Roche Molecular Biochemicals, Lewes, UK). Samples were pre-
clearedwith 40l of protein-G Sepharose beads (which had beenwashed
in NETF buffer to give a 50% slurry), and immunoprecipitations were
performed with monoclonal anti-V5 antibody preadsorbed onto
protein-G Sepharose beads. The protein-G Sepharose-bound immune
complexes were washed twice in NETF buffer containing 2 mM or-
thovanadate and NP-40 (1% w/v) and once in NETF without detergent.
Pellets from the immunoprecipitations were heated at 95°C for 5 min in
70 l of SDS-PAGE sample buffer (Laemmli, 1970) for SDS-PAGE.
Western blot analysis.Denaturing gel electrophoresis was performed as
described previously (Derkinderen and Girault, 1997; Williamson et al.,
2002) using 8 or 10% (w/v) polyacrylamide gels. Blots were visualized
using enhanced chemiluminescence detection (Amersham Biosciences).
Quantification was achieved by scanning the developed films with a
GS710 Calibrated Imaging Densitometer (Bio-Rad, Hemel Hempstead,
UK) and measuring relative optical density with Quantity One 4.0.3
software (Bio-Rad). Phosphotyrosine immunoreactivities with 4G10
were normalized for tau concentration using TP70 antibody and ex-
pressed as a percentage of the values obtained for the wild-type construct
(WT) (SEM). Graph Pad Prism 4.0 software was used for statistical
analysis.
In vitro phosphorylation of tau. Recombinant human tau (1 g) was
incubatedwith orwithout 0.5g of c-Abl (Upstate Ltd) in 30l of kinase
buffer (50 mM HEPES, pH 7.4, 10 mM MnCl2) in the presence of 1 mM
ATP for 30 min at 30°C. SDS-PAGE sample buffer (30 l) was added to
stop the reaction. Control tau was put through the same procedure but
without kinase.
Immunocytochemistry.Human tissue samples were obtained from au-
topsy material following approval of the Ethic Committee of the School
of Medicine of the Free University of Brussels. Tissue blocks of the hip-
pocampus and the parahippocampal gyrus in two control subjects (81
and 86 years of age) and in two patients with Alzheimer’s disease (84 and
91 years of age) were fixed by immersion in 10% (v/v) formalin for 3
weeks. Tissue samples were embedded in paraffin and cut in tissue sec-
tions with a thickness of 10m.TheAlzheimer’s disease patients fulfilled
the neuropathological criteria for stages V-VI according to the Braak
nomenclature.
Double immunocytochemical labeling was performed as reported
previously (Leroy et al., 2002). Briefly, tissue slides were incubated se-
quentially with 10% (v/v) normal goat serum in TBS (10 mM Tris-HCl,
pH 7.4/0.15 M NaCl) for 1 h and with the K-12 c-Abl polyclonal and the
AT8 monoclonal antibodies [diluted 1/1000 and 1/100, respectively, in
TBS containing 1% (v/v) normal goat serum] overnight. The c-Abl an-
tibody was detected by a goat anti-rabbit antibody conjugated to biotin
(Vector Laboratories, Burlingame, CA), followed by streptavidin conju-
gated to peroxidase and incubation with Alexa 488-tyramide (Molecular
Probes, Eugene, OR); the AT8 antibody was detected by a goat anti-
mouse antibody conjugated to Alexa 594 (Molecular Probes). The sec-
tions were then treated with 4,6-diamidino-2-phenylindole (DAPI) for
nuclear staining. Tissue sections were examined under UV illumination
with a Zeiss (Welwyn Garden City, UK) Axioplan microscope, and dig-
ital images were acquired using an Axiocam HRc camera.
Results
Tyrosine 394 is phosphorylated in PHF tau and in tau from
human fetal brain
Paired helical filament tau is known to be hyperphosphorylated
on numerous sites. Most of the sites reported to date have in-
volved serine or threonine, but a recent report identified phos-
phorylation of Tyr-18 using antibodies (Lee et al., 2004). PHF tau
was digested with trypsin, and the peptides were analyzed by
LC/MS/MS using the QTof-micro mass spectrometer. A doubly
charged precursor ion of m/z 1188 containing residues 386–406
was generally found to give weak fragment ions of m/z 1194 and
1211; these could represent the b10 ion and y12–98 ion, respec-
tively (i.e., y12 with loss of 98 Da as phosphate), derived from the
doubly phosphorylated peptide sequence TDHGAEIVpYKSPV-
VSGDTpSPRwith phosphates attached at residues 9 and 19 (Tyr-
394 and Ser-404 of tau, the latter as dehydroalanine). These ions
with m/z 1194 and 1211 discriminate between phosphorylation
of residue 9 of the peptide (Tyr-394) and phosphorylation on
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residue 11 (Ser-396). However, using the automated switching
mode of the QTof-micro mass spectrometer, the MS/MS spectra
obtained were typically heterogeneous and contained fragment
ions that also indicated the presence of another distinct phos-
phopeptide, TDHGAEIVYKpSPVVSGDTpSPR, with phos-
phates attached at residues 11 and 19 (Ser-396 and Ser-404 of
tau). These two peptides have the same molecular mass and
amino acid sequence and the same number of phosphate groups,
but these are attached to different amino acidswithin the peptide.
Therefore, both forms give rise to precursor ions of the samem/z,
and in this case, although they are resolved chromatographically,
there are no distinct MS/MS spectra. To confirm phosphoryla-
tion of Tyr-394, the novel MS/MS scan functions of the
4000QTRAP were exploited. The m/z 1188 precursor ion gave
two distinct EPI spectra, eluting at 31.9 min (Fig. 1A) and 32.7
min (Fig. 1B); only the latter yielded the fragments of m/z 1194
(b10) and 1211 (y12–98) that are diagnostic of pTyr-394 in this
peptide. This confirms that phosphorylated Tyr-394 was present
in PHF tau.
In analogous experiments using Asp-N digests of tau from
human fetal brain, the peptides were analyzed by LC/MS/MS
using the QTof-micro mass spectrometer. One was identified as
containing residues 387–401 of tau with two phosphate groups; its
fragmentation spectrum is shown in Figure 1C. The fragment ions
showunequivocally thatphosphatewaspresentonTyr-394,whereas
Ser-396was unphosphorylated. It was deduced that Ser-400was the
site of the second phosphate, identified here as dehydroalanine.
Therefore, the sequence of the peptide is DHGAEIVPYKSPVVPSG.
These results show that phosphorylation of tau on Tyr-394
may be a normal physiological event and also that it could be
involved in the pathological process leading to tau aggregation.
We therefore wanted to determine whether normal cells contain
endogenous kinases that can phosphorylate tau on tyrosine and,
if so, on which sites.
Tau is primarily phosphorylated on Tyr-394 in
pervanadate-treated cells
To induce tyrosine phosphorylation of tau in transfected COS-7
and SHSY5Y cells, we used the protein-tyrosine phosphatase in-
hibitor pervanadate. Pervanadate is a cell-permeant inhibitor of
protein-tyrosine phosphatases that acts by irreversible oxidation
of the catalytic site of these enzymes (Huyer et al., 1997). Cells
expressing wild-type tau (V5-tagged) were treated with pervana-
date (100 M for 20 min), or control-treated (see Materials and
Methods) were lysed, and the tau was immunoprecipitated with
anti-V5 antibody. The extracts were analyzed in duplicate by
Western blotting with antibodies to phosphotyrosine (4G10) or
tau (TP70). As shown in Figure 2, tau is phosphorylated in re-
sponse to pervanadate, whereas treatment of cells with hydrogen
peroxide and catalase results in no change in tyrosine phosphor-
ylation of tau.
To map the phosphorylated tyrosine residues, constructs of
tau with one tyrosine changed to phenylalanine (Y18F, Y29F,
Figure 1. Mass spectrometric identification of phosphorylated tyrosine 394 in tau from PHF
and in fetal tau bymass spectrometry. A, PHF tau was isolated from Alzheimer brain tissue and
digestedwith trypsin for analysis by LC/MS/MS. Themass/charge ratio is plotted against inten-
sity. Part of the EPI spectrum is shown of the doubly charged precursor peptide of m/z 1188.3
eluting at 31.9 min, TDHGAEIVYKpSPVVSGDTpSPR (tau residues 386–406). B, As in A but
eluting at 32.7min. The peak ions ofm/z 1194 (b10) and 1211 (y12–98), which are not present
inA, show that the precursor peptide is TDHGAEIVpYKSPVVSGDTpSPR [i.e., it is phosphorylated
on residue 9 (Tyr-394) and not on residue 11 (Ser-396)]. The nomenclature is as described by
Roepstorff and Fohlman (1984). C, Tau from human fetal brain tissue was isolated and purified
by gel electrophoresis, digested with Asp-N, and analyzed by LC/MS/MS. The fragmentation
spectrum is shown for the peptide DHGAEIVPYKSPVVPSG (tau residues 387–401). The y ion
series demonstrates that Tyr-394 is phosphorylated (ions of the m/z of y8 and above contain
phosphate, whereas y6 and below do not), and that Ser-400 is dehydroalanine (mass 69 in all
identified y ions) caused by loss of phosphate in the fragmentation reaction,whereas Ser-396 is
intact nonphosphorylated serine.
Figure 2. Tau is phosphorylated on tyrosine in pervanadate-treated COS-7 cells. COS-7 cells
were transiently transfectedwith either empty vector (mock; right lane) or V5-tagged tau (WT;
center lane) and treated for 20minwith pervanadate (100M sodiumorthovanadate and4mM
H2O2 and catalase). As a control, cells transfected with V5-tagged tau (2N4R; left lane) were
treatedwithhydrogenperoxide and catalasebutwithout sodiumorthovanadate. Immunoblots
were performed on duplicate membranes using 4G10 antiphosphotyrosine antibody (IP V5,
Blot P-Tyr) or anti-tau TP70 antibody (IP V5, Blot Tau).
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Y197F, Y310F, and Y394F) were trans-
fected into COS-7 cells and treated with
pervanadate. Western blot analysis
showed that the Y394F mutation is the
only single-tyrosine mutation that re-
sulted in a significant effect, reducing
phosphotyrosine immunoreactivity to
10% of the wild-type control (Fig.
3A,B). This suggests thatmost, but not all,
of the endogenous tyrosine phosphoryla-
tion of tau in COS-7 cells occurs on Tyr-
394. Similar results were obtained using
P-Tyr-100 antiphosphotyrosine antibody
(data not shown). Tyrosine phosphoryla-
tion of the Y18F, Y29F, Y197F, and Y310F
constructs was not significantly different
from the wild-type control. For the Y197F
mutant construct, however, a modest de-
crease in tyrosine phosphorylationwas ob-
served in some experiments.
To confirm these results, we trans-
fected each of five other tau mutants in
which only one tyrosine residue remained,
with the other four replaced by phenylala-
nine, intoCOS-7 cells and treated them for
20 min with pervanadate. Analysis using
phosphotyrosine antibodies showed that
little or no tyrosine phosphorylation could
be detected after treatment with pervana-
date in cells expressing Y18only, Y29only,
Y197only, or Y310only, whereas pervana-
date induced an increase in phosphoty-
rosine staining of Y394only, similar to that observed with wild-
type tau (Fig. 3C,D). Together, these results show that, in
pervanadate-treated COS-7 cells, phosphorylation occursmainly
on Tyr-394, with a little phosphorylation on other tyrosine resi-
dues in tau.
To determine whether Tyr-394 is also the principal site of
tyrosine phosphorylation on tau in cells of neuronal origin,
SHSY5Y neuroblastoma cells were transiently transfected with
V5-tagged wild-type or Y394F tau constructs. After pervanadate
treatment, the wild-type tau, but not the Y394F mutant, showed
substantial tyrosine phosphorylation (Fig. 3E). This suggests that
the endogenous tyrosine kinases in neuronal SHSY5Y cells, as in
fibroblasts, preferentially phosphorylate tau on Tyr-394.
Both Src-family kinases and c-Abl bind to and
phosphorylate tau
To elucidate which protein tyrosine kinases might be involved in
the tyrosine phosphorylation of tau in cells observed with per-
vanadate, we used PP2, an inhibitor of Src-family kinases, and its
counterpart, PP3, a related compound that inhibits epidermal
growth factor receptor activation but not Src-family kinases
(Hanke et al., 1996). Western blot analysis using SRC-2 antibody
revealed that COS-7 cells express Src-family kinase members
(data not shown).Wild-type tau was transfected into COS-7 cells
and pretreated with 10M PP2, PP3, orDMSO-vehicle control for
1 h before treatment with pervanadate. Pretreatment of cells with
PP2 strongly decreased the tyrosine phosphorylation of tau induced
by pervanadate, whereas PP3 did not (Fig. 4). These results suggest
that Src-family or other related kinases are involved in tau tyrosine
phosphorylation.
To determine more directly whether Src-family members can
phosphorylate tau in cells, cotransfection experiments were per-
formed in CHO cells using c-Src or Fyn expression vectors along
with the wild-type tau construct without pervanadate treatment.
CHO cells were used in these double-transfection experiments.
Western blot analysis was then performed on immunoprecipi-
tated tau using the anti-phosphotyrosine (4G10) and anti-tau
(TP70) antibodies and on total cell lysates using SRC-2 antibody.
As illustrated in Figure 5, cotransfection of c-Src or Fyn with tau
results in increased tyrosine phosphorylation of tau in CHO cells.
The phosphotyrosine immunoreactivity of tau was weaker in all
experiments performedwith Fyn comparedwith thosewith c-Src
(Fig. 5A). When Fyn or c-Src were cotransfected with tau, tau
immunoprecipitates contained a 60 kDa band that migrated
between the immunoglobulin heavy chains and tau. The 60 kDa
band is likely to contain Src or Fyn, because these enzymes are
tyrosine phosphorylated and are known to interact with tau
through their SH3 domains(Lee et al., 1998). The presence of
Src-family kinases in the 60 kDa band was confirmed by blotting
with SRC-2 antibody (Fig. 5C). Western blot analysis of total
lysates confirmed that c-Src and Fyn were expressed strongly in
transfected cells and weakly in control (tau plus empty vector)
cells (Fig. 5D).
However, Fyn is reported to phosphorylate tau primarily on
Tyr-18 (Lee et al., 2004), raising the possibility that endogenous
phosphorylation on Tyr-394 may be attributable to another ki-
nase that is also sensitive to PP2. Although initially identified as
high-potency inhibitors of Src tyrosine kinases (Hanke et al.,
1996), PP1 and PP2 also inhibit the nonreceptor tyrosine kinase
c-Abl with a similar potency (Liu et al., 1999; Tatton et al., 2003;
Warmuth et al., 2003). In contrast, PP3, an analog of PP1 and
PP2, has no effect on c-Abl activity (Traxler et al., 1997). Because
Figure3. Tau is phosphorylatedon tyrosine394 inpervanadate-treatedCOS-7 cells.A, COS-7 cellswere transiently transfected
with V5-tagged constructs expressing human tau (2N4R, WT) or withmutants of tau in which one tyrosine had been replaced by
phenylalanine (Y18F, Y29F, Y197F, Y310F, and Y394F). Cells were treated with 100M pervanadate for 20min. Immunoprecipi-
tation andWestern blot analysis were performed as described for Figure 2. B, Phosphotyrosine immunoreactivity was expressed
as a percentage of the value obtained for the wild-type construct (SEM). Themean values for each construct were determined
frommultiple filmexposure in threedifferent experiments for Y18F, Y29F, andY310F, five different experiments for Y197F, and11
different experiments for Y394F. C, COS-7 cellswere transiently transfectedwith V5-tagged tau constructs, eitherWT orwith only
one tyrosine remaining (Y18only, Y29only, Y197only, Y310only, or Y394only). Cells were treatedwith pervanadate for 20min.D,
Immunoreactivity for each Yonly construct with 4G10 was quantified as described above in three separate experiments. The
one-sample t test was used for statistical evaluations. Y394Fwas the only construct resulting in a statistically significant decrease
in tau phosphorylation compared with the WT construct ( p 0.0001). E, SHSY5Y cells were transfected with V5-tagged wild-
type or Y394F-tau and treated and analyzed as in A.
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c-Abl is expressed in both COS-7 and CHO cells (data not
shown), this suggests that some of the effects of PP2 on the ty-
rosine phosphorylation of taumay be attributable to inhibition of
c-Abl. c-Abl is expressed in the brain, where it plays a critical role
in neuronal development (Koleske et al., 1998), and the sequence
flanking Tyr-394 on tau (VYKSP) matches the optimal substrate
sequence for c-Abl (I/VYXXP) (Wu et al., 2002; Obenauer et al.,
2003).
Therefore, to determine whether c-Abl can phosphorylate tau
in CHO cells, cotransfection experiments were performed using
c-Abl and c-AblXB expression vectors. c-AblXB, a constitu-
tively active mutant of c-Abl, was used because the basal kinase
activity of c-Abl is low. Both c-Abl and c-AblXB, but not the
empty vector, induce an increase in tau tyrosine phosphorylation
when cotransfected with tau into CHO cells (Fig. 6A). As pre-
dicted, the increase of tau tyrosine phosphorylation was greater
with c-AblXB than with c-Abl. c-Abl could be phosphorylating
tau directly or indirectly by acting through c-Abl-activated path-
ways involving other kinase(s). To help distinguish between these
two possibilities, in vitro phosphorylation assays using purified
c-Abl and tau were performed. Tau was phosphorylated in vitro
by c-Abl as judged onWestern blots with 4G10, whereas no phos-
phorylation was observed in experiments in which tau was incu-
bated without c-Abl (Fig. 6B). These results demonstrate that
c-Abl is indeed a tau kinase.
When Abl or AblXB was cotransfected with tau, tau immu-
noprecipitates contained a140 kDa band, recognized by phos-
photyrosine antibodies (data not shown). This band was sus-
pected to containAbl or its truncated and activated form, because
these enzymes are tyrosine phosphorylated. This was confirmed
by blotting the tau immunoprecipitation with c-Abl antibodies
(Fig. 6C), showing that c-Abl binds to tau.
Tyrosine 394 is the primary residue in tau phosphorylated
by c-Abl
Tomap the tyrosine residue(s) phosphorylated by c-Abl and Fyn
in tau, each kinase was cotransfected into CHO cells along with
wild-type or mutant tau constructs in which individual tyrosines
were replaced by phenylalanine.
As observed previously with pervanadate (Fig. 3A), when
c-AblXB was cotransfected with the Y394F mutant construct,
there was a strong decrease in tyrosine phosphorylation com-
pared with the wild-type construct (Fig. 7A). Cotransfection of
c-Abl with Y197F or Y310F resulted in a moderate but reproduc-
ible decrease in tau tyrosine phosphorylation (Fig. 7A). In con-
trast, tyrosine phosphorylation of the Y18F and Y29F constructs
was not significantly different from the wild-type control. This
indicates that tyrosine 394 is the major tyrosine phosphorylation
site in c-Abl-cotransfected cells. Cotransfection of Fyn with the
same tau constructs gave strikingly different results: Y18F is the
only single-tyrosine mutation that results in a significant effect,
Figure 4. PP2, an Src family and c-Abl kinase inhibitor, prevents the pervanadate-induced
tyrosine phosphorylation of tau. COS-7 cells were transiently transfected with V5-tagged tau
andpretreated for 1hwithPP2orPP3and then treatedwithpervanadate for 20min, harvested,
immunoprecipitated, and analyzed by Western blot analysis. Quantification was performed,
and results show the mean values SEM from four separate experiments.
Figure 5. The Src family kinases, c-Src and Fyn, phosphorylate tau in transfected CHO cells.
CHO cells were cotransfected with V5-tagged human tau and constructs expressing Src
(TauSrc), Fyn (TauFyn), or empty vector (TauEV). Cells were harvested, and tau was
isolatedby immunoprecipitation (IP V5); blotswere probed inAwith 4G10 (IP V5, Blot P-Tyr), in
Bwith TP70 (IPV5, Blot Tau), and inCwith thepan-Src antibodySRC-2demonstrating that both
Src and Fynwere coimmunoprecipitatedwith tau (IP V5, Blot SRC-2).D showsWestern blots of
cell lysates before immunoprecipitation to demonstrate transfection of the kinases using SRC-2
antibody.
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reducing phosphotyrosine immunoreac-
tivity to 20% of the wild-type control
(Fig. 7B). Cotransfection of Fyn with
Y310F, in two of the four experiments that
were conducted, resulted in a decrease in
tau phosphorylation. In contrast, tyrosine
phosphorylation of the Y29F, Y197F, and
Y394F constructs were not significantly
different from the wild-type control. To-
gether, these results show that c-Abl and
Fyn phosphorylate different sites on tau:
Tyr-18 is the major tyrosine phosphoryla-
tion site for Fyn, whereas Tyr-394 is the
major site for c-Abl.
Abl is induced and redistributed in
pretangle neurons in Alzheimer’s
diseased brain
When tissue sections from the hippocam-
pus of AD or control brains were immu-
nolabeled using anti-c-Abl antibody, the
majority of cells showed only very weak
and diffuse labeling. In AD cases, however,
a population of neurons in the Ammon’s
horn of the hippocampus and in the adja-
cent temporal cortex showed a granular
and faintly diffuse cytoplasmic Abl label-
ing. Dual labeling was performed using
AT8, a monoclonal antibody that recog-
nizes a phosphorylated epitope in PHF tau
and stains classic NFT and also pretangle
neurons that already have some tau pa-
thology but not normal healthy neurons.
The majority of cells showing diffuse Abl
immunoreactivity were also AT8 positive,
with granular and patchy tau-positive ma-
terial, as seen in the early stages of tangle
formation. Some neurons were stained
more strongly with AT8, and this immu-
noreactivity partially colocalized with the
Abl immunoreactivity (Fig. 8A–C). At
least some of the Abl-positive granules (Fig. 8, arrowheads) cor-
responded to the central granules of granulovacuolar degenera-
tion (GVD). Occasional GVD was also labeled in the control
cases. In three AD cases examined, 6  1% (SEM) of the AT8-
positive neurons were also Abl positive. It seems that as NFTs
develop in neurons, these cells are Abl positive, and the Abl is
often enriched in cytoplasmic granules; however, in neurons that
contain mature tangles, the Abl appears not to persist at elevated
levels (Fig. 8D–F). Therefore, during NFT formation, Abl is re-
distributed and apparently elevated in at least some neurons, in
which Abl and tau can show a considerable amount of colocal-
ization (Fig. 8A–C). This is consistent with Abl having a role in
the development of tau pathology.
Discussion
Wehave identified by LC/MS/MS that Tyr-394 is phosphorylated
in PHF tau from theADbrain and in human fetal brain tau. These
results demonstrate that phosphorylation of tau on Tyr-394 is a
physiological event, which could also be involved in the process
leading to neurodegeneration in the tauopathies. Using two dif-
ferent antibodies that recognize phosphotyrosine 18, tau was
shown to be phosphorylated onTyr-18 in the fetalmouse brain as
well as in PHF preparations and NFTs in situ (Lee et al., 2004),
confirming the tyrosine phosphorylation of PHF tau we reported
previously (Williamson et al., 2002). The sequence flanking Tyr-
394 in tau is highly conserved between mammalian species (hu-
man, rhesus monkey, rat, mouse, goat, and cow) (Nelson et al.,
1996). In contrast, the region of tau containing Tyr-18 and
Tyr-29 in the human and rhesus monkey is quite dissimilar to
that in the other species that lack a stretch of 10 or 11 amino acids
that includes one of these two tyrosines. Phosphorylation at Tyr-
18, therefore, could have a role in the development of tauopa-
thies, which seem to be a primarily human phenomenon.
Equally, phosphorylation at Tyr-394 could also be involved in
both physiological and pathological roles of tau, and thus it is
important to identify the kinase or kinases that phosphorylate
Tyr-394.
In the second part of the study, we determined whether Tyr-
394 is themain tyrosine residue phosphorylated in tau andwhich
kinases are involved in tau tyrosine phosphorylation. Most cells
exhibit low steady-state protein phosphotyrosine levels, reflect-
ing the tight regulation of protein tyrosine kinase activity and the
relatively high ratio of the activity of tyrosine phosphatases to
tyrosine kinases (Girault, 1993; Hunter, 1995). Thus, to study tau
Figure 6. c-Abl phosphorylates tau in both transfected CHO cells and by direct in vitro phosphorylation. A, CHO cells were
cotransfected with V5-tagged wild-type human tau and c-Abl (Tauc-Abl), c-AblXB (Tau c-AblXB) expression vector
constructs, or empty vector (TauEV). Both immunoprecipitated tau and total lysates were separated using an 8% gel. Western
blot analysis was performed on all samples using 4G10 (Blot PTyr), TP70 (Blot Tau), or Abl (Blot Abl) antibodies. B, Recombinant
tau was incubated in the absence or in the presence of recombinant c-Abl with ATP at 30°C for 30 min. The phosphorylation
reactions were analyzed by Western blotting using 8% gels and 4G10 (Blot PTyr) and TP70 (Blot Tau). C, Cells were transfected,
immunoprecipitated with anti-V5 antibody, and analyzed as in A using anti-Abl antibody for probing.
Figure 7. Tyr-394 is themajor site phosphorylated in tau by c-Abl, whereas Tyr-18 is the primary site phosphorylated by Fyn in
transfected CHO cells. Cells were cotransfected with constructs expressing c-AblXB (A), Fyn (B), or empty vector (EV) and with
constructs for V5-tagged human tau (WT) or with V5-tagged mutants of tau (Y18F, Y29F, Y197F, Y310F, Y394F). Western blots
were probed as indicated, with 4G10 (Blot PTyr), TP70 (Blot Tau), c-Abl s.c.-23 (Blot Abl), c-Abl [pY 412] (Blot Abl-PY), SRC-2 (Blot
SRC-2), and Phospho-Src family, Tyr-416 (Blot Fyn-PY). The data presented are representative of three independent experiments.
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tyrosine phosphorylation in cells, we used the protein tyrosine
phosphatase inhibitor pervanadate in COS cells transfected with
different tau constructs. The tyrosine phosphorylation of tau in
response to pervanadate occurs primarily on Tyr-394 with little
phosphorylation occurring on the other tyrosine residues. Also,
in SHSY5Y neuroblastoma cells, the Y394F mutant showed a
strong reduction in phosphorylation, suggesting that, here also,
Tyr-394 is the main site for tyrosine phosphorylation. A recent
report showed that Tyr-18 is themain tyrosine residue phosphor-
ylated in tauwhenboth tau andFynare cotransfected intoCOScells
(Lee et al., 2004). This apparent discrepancy suggested to us that tau
might be phosphorylated by an endogenous kinase other than Fyn.
Treatment of cells with the tyrosine kinase inhibitor PP2 dra-
matically decreased the pervanadate-induced tyrosine phosphor-
ylation of tau, suggesting that Src-family kinases could be in-
volved in tau phosphorylation in cells (Hanke et al., 1996).
Although PP2 was originally described as a specific inhibitor of
the Src-family kinases, subsequent reports showed that PP2 and
closely related compounds such as PP1 also inhibit the tyrosine
kinase c-Abl (Liu et al., 1999; Tatton et al., 2003; Warmuth et al.,
2003). Interestingly, the sequence flanking Tyr-394 does not
match the consensus sequence for Src and Fyn (Songyang and
Cantley, 1995; Dente et al., 1997) but resembles the known ca-
nonical substrate sequence determined for c-Abl (Songyang and
Cantley, 1995; Dente et al., 1997;Wu et al., 2002; Obenauer et al.,
2003). This led us to investigate c-Abl as a candidate tau kinase.
Cotransfection of Abl and tau resulted in highly preferential
phosphorylation of tau on Tyr-394 in cells, and recombinant Abl
was shown to phosphorylate recombinant tau in vitro.
The c-Abl family of nonreceptor tyrosine kinases consists of
c-Abl and its only paralog Arg. c-Abl is a ubiquitously expressed
140 kDa protein, which is localized at several subcellular sites (for
review, see Van Etten, 1999; Pendergast, 2002; Hantschel and
Superti-Furga, 2004). c-Abl and Arg contain SH3 and SH2 do-
mains in tandem and share C-terminal actin-binding domains
that are not found in other tyrosine kinases. Through these do-
mains, cytoplasmic c-Abl associates with F-actin bundles and
focal adhesions (Van Etten et al., 1994). There is mounting evi-
dence that Abl-family kinases play a key role in the development
of the CNS. Mice lacking both c-Abl and Arg show neural tube
defects (Koleske et al., 1998), and c-Abl promotes neurite exten-
sion in cortical neurons (Zukerberg et al., 2000; Woodring et al.,
2002) and dendritogenesis in hippocampal neurons (Jones et al.,
2004). The abl gene is conserved in invertebrates, andDrosophila
Abl functions in axon guidance through binding to a multimo-
lecular complex (Van Etten, 1999; Moresco and Koleske, 2003).
c-Abl is already medically important, because mutations of
this kinase cause several leukemias in humans (Van Etten, 1992,
2004). Our finding of phosphorylation of Tyr-394 in PHF tau
isolated from an AD brain suggests that excess tyrosine phos-
phorylation of tau may be involved in the development of Alz-
heimer pathology. Tyrosine-18 was also shown from immuno-
logical data to be phosphorylated in someNFTs (Lee et al., 2004).
Treatment of hippocampal cells with fibrillar A increased both
the expression and activity of c-Abl and also induced apoptosis
(Alvarez et al., 2004). Inhibition of Abl activity with STI571 (4-[(4-
methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-
yrimidinyl]amino]-phenyl]benzamide) protected hippocampal
neurons from A-induced apoptosis, and suppression of Abl
mRNA levels protected NR2a cells from A-induced toxicity (Al-
varez et al., 2004). Interestingly, tau is essential for the neurotoxicity
induced by A (Rapoport et al., 2002), and we reported previously
thatA induced thephosphorylationof tauontyrosine (Williamson
et al., 2002). Thus, it is tempting to speculate that the Abl-induced
toxicity is mediated through the tyrosine phosphorylation of tau by
c-Abl. This is strengthened by our finding that Abl distribution was
altered in neurons from AD brain, with elevated amounts in some
neurons, particularly pretangle neurons. This could be secondary to
induction of c-Abl by A or by oxidative products of local inflam-
mation(Alvarezet al., 2004).Ourdemonstrationofbindingof tau to
c-Abl and c-AblXB is consistent with tau being a specific substrate
forAbl and for their involvement in a cell-signaling pathway.Unlike
Src-family kinases, which interact with tau through their SH3 do-
mains (Lee et al., 1998), c-Abl is likely to use a differentmechanism.
The SH3 domain of c-Abl is deleted partially in c-AblXB, yet this
protein interacted with tau similarly to native c-Abl. Furthermore,
the SH3 of Abl did not bind to tau (Lee et al., 1998).
The finding that Abl is elevated in neurons that are in the early
stages of tangle formation raises the possibility that tyrosine
phosphorylation may initiate or promote tau aggregation. Stress
activation of c-Abl leads to various downstream effects, including
activation of serine/threonine protein kinases (Van Etten, 1999).
At least one of these, c-Jun N-terminal kinase, is a known tau
kinase, which phosphorylates tau sites that are found to be phos-
phorylated in PHF (Goedert et al., 1997; Reynolds et al., 1997,
2000). Furthermore, another tau kinase, cdk5, which is thought
to be important in the generation of tau pathology (Noble et al.,
2003), can be phosphorylated and activated by c-Abl (Zukerberg
Figure 8. Immunofluorescence labeling of Abl in a subpopulation of NFT-containing neu-
rons. Hippocampal sections from an AD brain were labeled with anti-c-Abl antibody visualized
with Alexa 488 green fluorophore (A, D) and with anti-phosphotau antibody AT8 visualized
with Alexa 594 red fluorophore (B, E), followed by DAPI staining of nuclei. Merged imageswith
DAPI staining are shown in C and F.A–C, An AT8-positive neuron (arrow) contains a tangle and
also an Abl-positive granule (A, arrowhead). An adjacent neuron (white circle) has a strong
AT8-positive tangle but gives only weak and diffuse Abl staining. D–F, Three neurons contain-
ing stronglyAT8-positiveNFT (asterisks), oneofwhich contains anAbl-positive granule. At least
40 AT8-positive neurons were examined from each of three AD brains, and 6 1% (SEM) of
these also stained positively for Abl.
Derkinderen et al. • Tyrosine Phosphorylation of Tau by c-Abl J. Neurosci., July 13, 2005 • 25(28):6584–6593 • 6591
et al., 2000). Therefore, as well as phosphorylating tau on ty-
rosine, c-Abl may promote pathological serine/threonine phos-
phorylation of tau. We were unsuccessful, however, in demon-
strating changes in serine/threonine phosphorylation using
phosphospecific antibodies (our unpublished observations). Ad-
ditionally, Abl can be activated by Src-family kinases (e.g., in
response to growth factors) (Plattner et al., 1999), and thus the
two candidate kinases, Abl and Fyn, may act in concert in some
situations.
It is also possible that phosphorylation of tau on Tyr-394 may
promote its aggregation directly, but we have not been able to
show increased aggregation in vitro of Abl-phosphorylated tau
(our unpublished observations). An indirect mechanism as out-
lined above may therefore be more likely.
Our finding of elevated Abl in pretangle neurons rather than
in neurons containing mature tangles suggests that the Tyr-394-
phosphorylated tau that we had identified by mass spectrometry
may have originated predominantly from pretangle neurons.
Studies are under way to develop phosphotyrosine-394-specific
antibodies that will enable this prediction to be tested by
immunolabeling.
However, we also foundphosphorylatedTyr-394 in fetal brain
tau, suggesting that this phosphorylation is a normal physiolog-
ical event. We have not found evidence that tyrosine phosphor-
ylation of tau affects binding to microtubules (our unpublished
observations), and phosphorylation of Tyr-18 was also reported
not to affect its binding to microtubules (Lee et al., 2004), sug-
gesting that tyrosine phosphorylation of tau may influence other
properties.
There is mounting evidence that tau plays a role in cell signal-
ing. Tau can interact with various signaling molecules, including
PLC- (Hwang et al., 1996; Jenkins and Johnson, 1998), Src-
family kinases (Lee et al., 1998), and protein phosphatases 1 (Liao
et al., 1998) and 2A (Sontag et al., 1999; Eidenmuller et al., 2001).
Moreover, tau and catalytically active Fyn are both required for
oligodendrocyte outgrowth (Klein et al., 2002). Any such signal-
ing role of tau may be distinct from its actions on microtubules.
Indeed, a proportion of tau in cells is bound to membranes
(Brandt et al., 1995;Maas et al., 2000). The results presented here
suggest that c-Abl is both a tau kinase and a binding partner.
In conclusion, our findings significantly contribute to the un-
derstanding of the signaling pathways involving tyrosine phos-
phorylation of tau in both physiological and pathological condi-
tions. Additional elucidation of the functional relationship
between tau and the Abl family of tyrosine kinases in neurons
could provide critical insights into the role of tau in cell signaling
and development as well as in neurodegenerative processes.
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